Crinetics upgraded to buy by Jefferies, atumelnant potential cited

Last updated: January 22, 2025 7:22 pm

By MT HANNACH

Add a Comment

0 Min Read

Disclosure: This website may contain affiliate links, which means I may earn a commission if you click on the link and make a purchase. I only recommend products or services that I personally use and believe will add value to my readers. Your support is appreciated!

Bull and bear figures on stock price list — Adam Gault

Jefferies upgraded Crinetics Pharmaceuticals (NASDAQ:CRNX) to buy, citing a recent pullback in the stock due to investor concerns over phase 2 data for the company’s drug atumelnant in the treatment of congenital adrenal hyperplasia, or CAH.

The investment bank said